AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12042887 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone treatment for 12 months
Number of subjects: 23
Study 12042887 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 23
Study 9527357 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine/thymol-containing varnish (Cervitec) applied twice within 3 days
Number of subjects: 25
Study 9527357 — intervention group
Group type: COMPARATOR
Intervention: Placebo varnish without active ingredients
Number of subjects: 25
Study 8583450 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound drainage
Number of subjects: 177
Study 8583450 — intervention group
Group type: COMPARATOR
Intervention: No wound drainage
Number of subjects: 177
Study 2378441 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (Bricanyl) 0.5 mg t.i.d. via Turbuhaler
Number of subjects: 36
Study 2378441 — intervention group
Group type: COMPARATOR
Intervention: Fenoterol (Berotec) 0.2 mg t.i.d. via Inhalator Ingelheim
Number of subjects: 36
Study 1092727 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen (500 mg/day)
Number of subjects: 119
Study 1092727 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (3.6 Gm/day)
Number of subjects: 119
Study 1092727 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen (250 mg twice daily)
Number of subjects: 119
Study 1092727 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 119
Study 1092727 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 119
Study 30500067 — intervention group
Group type: EXPERIMENTAL
Intervention: SCP care
Number of subjects: 225
Study 28292223 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual-reality job interview training (VR‐JIT)
Number of subjects: 79
Study 28292223 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion of virtual interviews
Number of subjects: 79
Study 25437827 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive cardiac rehabilitation
Number of subjects: 196
Study 25437827 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 196
Study 24053114 — intervention group
Group type: EXPERIMENTAL
Intervention: Teledentistry examination
Number of subjects: 291
Study 24053114 — intervention group
Group type: COMPARATOR
Intervention: Traditional visual tactile examination
Number of subjects: 291
Study 21482368 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol
Number of subjects: 200
Study 21482368 — intervention group
Group type: COMPARATOR
Intervention: Vaginal dinoprostone
Number of subjects: 200
Study 17938939 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine with biofeedback therapy (group A)
Number of subjects: 21
Study 17938939 — intervention group
Group type: COMPARATOR
Intervention: Biofeedback therapy alone (group B)
Number of subjects: 21
Study 17938939 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 21
Study 16257388 — intervention group
Group type: EXPERIMENTAL
Intervention: High personal standards condition (n = 18)
Number of subjects: 41
Study 16257388 — intervention group
Group type: COMPARATOR
Intervention: Low personal standards condition (n = 23)
Number of subjects: 41
Study 12620169 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% lidocaine and 0.3% nifedipine applied twice daily for 6 weeks
Number of subjects: 0
Study 10964191 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in relaxation, cognitive restructuring, and communication skills; Duration: Immediate training.
Number of subjects: 61
Study 10964191 — intervention group
Group type: COMPARATOR
Intervention: Control group with training delayed for 6 months.
Number of subjects: 61
Study 8626984 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with Dermatophagoides extract
Number of subjects: 88
Study 8626984 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 88
Study 1370507 — intervention group
Group type: EXPERIMENTAL
Intervention: Detirelix 1 mg
Number of subjects: 6
Study 1370507 — intervention group
Group type: EXPERIMENTAL
Intervention: Detirelix 5 mg
Number of subjects: 6
Study 1370507 — intervention group
Group type: EXPERIMENTAL
Intervention: Detirelix 20 mg
Number of subjects: 6
Study 1370507 — intervention group
Group type: EXPERIMENTAL
Intervention: Detirelix 5 mg and 20 mg
Number of subjects: 6
Study 6707342 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg)
Number of subjects: 19
Study 6707342 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (20 mg)
Number of subjects: 19
Study 6707342 — intervention group
Group type: EXPERIMENTAL
Intervention: Both nifedipine and isosorbide dinitrate
Number of subjects: 19
Study 6707342 — intervention group
Group type: COMPARATOR
Intervention: Propranolol alone
Number of subjects: 19
Study 28704314 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual feedback during barbell back squat
Number of subjects: 0
Study 28704314 — intervention group
Group type: COMPARATOR
Intervention: Control (no visual feedback)
Number of subjects: 0
Study 28704314 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual feedback
Number of subjects: 0
Study 29161930 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific positioning guides (PSPGs)
Number of subjects: 109
Study 29161930 — intervention group
Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 109
Study 26509816 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent weaning pattern
Number of subjects: 145
Study 26509816 — intervention group
Group type: COMPARATOR
Intervention: Steady weaning pattern
Number of subjects: 145
Study 24281893 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 9
Study 24281893 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Citrate
Number of subjects: 9
Study 24281893 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Caffeine and Sodium Citrate
Number of subjects: 9
Study 24281893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 22862827 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant 40 mg
Number of subjects: 176
Study 22862827 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron 4 mg
Number of subjects: 176
Study 20702609 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 μg I/d supplementation
Number of subjects: 109
Study 20702609 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 μg I/d supplementation
Number of subjects: 109
Study 20702609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 20702609 — intervention group
Group type: COMPARATOR
Intervention: Unsupplemented women
Number of subjects: 109
Study 16583464 — intervention group
Group type: EXPERIMENTAL
Intervention: LD-rofecoxib (0.3 mg/kg/day up to 12.5 mg/day)
Number of subjects: 310
Study 16583464 — intervention group
Group type: EXPERIMENTAL
Intervention: HD-rofecoxib (0.6 mg/kg/day up to 25 mg/day)
Number of subjects: 310
Study 16583464 — intervention group
Group type: COMPARATOR
Intervention: naproxen (15 mg/kg/day)
Number of subjects: 310
Study 12664078 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP‐2 infusion (25 pmol/kg body weight) for 4.5 hours
Number of subjects: 18
Study 12664078 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 18
Study 11105737 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 182
Study 11105737 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study 9169336 — intervention group
Group type: EXPERIMENTAL
Intervention: UVB plus calcipotriene 0.005% ointment twice daily
Number of subjects: 20
Study 9169336 — intervention group
Group type: COMPARATOR
Intervention: UVB plus mineral oil
Number of subjects: 20
Study 1414449 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group viewed a 6-minute videotape explaining reasons to wear seat belts.
Number of subjects: 326
Study 1414449 — intervention group
Group type: COMPARATOR
Intervention: Control group viewed a videotape espousing general preventive health care guidelines with no mention of seat belts.
Number of subjects: 326
Study 3886302 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg mecillinam daily for 14 days
Number of subjects: 32
Study 3886302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 30554092 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids and vitamin E co-supplementation (1000 mg/day of omega-3 from flaxseed oil plus 400 IU/day of vitamin E)
Number of subjects: 40
Study 30554092 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 29800375 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (1-2 mg/kg IV bolus, then continuous infusion starting at 5 mcg/kg/min, titrated as needed)
Number of subjects: 17
Study 29800375 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 17
Study 27780506 — intervention group
Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment (MoCA)
Number of subjects: 230
Study 27780506 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-Mental State Examination (MMSE)
Number of subjects: 230
Study 27780506 — intervention group
Group type: EXPERIMENTAL
Intervention: MoCA
Number of subjects: 230
Study 27780506 — intervention group
Group type: EXPERIMENTAL
Intervention: MoCA and MMSE
Number of subjects: 230
Study 24333038 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based multi-component personalized feedback intervention
Number of subjects: 263
Study 24333038 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 263
Study 22345630 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal behavioral treatment (MBT)
Number of subjects: 76
Study 22345630 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptans
Number of subjects: 76
Study 22345630 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesics
Number of subjects: 76
Study 22345630 — intervention group
Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 76
Study 19929593 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine transdermal patch with concomitant memantine
Number of subjects: 261
Study 19929593 — intervention group
Group type: COMPARATOR
Intervention: Rivastigmine transdermal patch without concomitant memantine
Number of subjects: 261
Study 17324688 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led home-based case management intervention (NHI)
Number of subjects: 121
Study 17324688 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 121
Study 16263779 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular corticosteroid injections (40 mg methylprednisolone acetate)
Number of subjects: 86
Study 16263779 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 12883695 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed dosing of epoetin alpha (10,000 IU)
Number of subjects: 546
Study 12883695 — intervention group
Group type: COMPARATOR
Intervention: Weight-based dosing of epoetin alpha (150 IU/kg)
Number of subjects: 546
Study 12883695 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 546
Study 10898435 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency exercise training (10 sessions per week for 6 weeks)
Number of subjects: 130
Study 10898435 — intervention group
Group type: COMPARATOR
Intervention: Low-frequency exercise training (2 sessions per week for 6 weeks)
Number of subjects: 130
Study 9182001 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial ablation by electrosurgery through a hysteroscopic sheet (9 mm) with glycocol distended media (1.5%)
Number of subjects: 342
Study 9182001 — intervention group
Group type: COMPARATOR
Intervention: Hysterectomy
Number of subjects: 342
Study 1398694 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 30
Study 1398694 — intervention group
Group type: COMPARATOR
Intervention: Methyldopa
Number of subjects: 30
Study 2861282 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (TZ) 0.5 to 3.0 mg
Number of subjects: 0
Study 2861282 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentobarbital (PTB) 100 to 600 mg
Number of subjects: 0
Study 2861282 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (TZ)
Number of subjects: 0
Study 2861282 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentobarbital (PTB)
Number of subjects: 0
Study 31785112 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (PUFAs)
Number of subjects: 474
Study 31785112 — intervention group
Group type: EXPERIMENTAL
Intervention: n-6 polyunsaturated fatty acids (PUFAs)
Number of subjects: 474
Study 29781596 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycloergometer training (CYC)
Number of subjects: 40
Study 29781596 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard exercises)
Number of subjects: 40
Study 26736023 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Avoidance Test (BAT-Back) for CLBP patients
Number of subjects: 97
Study 26736023 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report measures for pain, pain-related fear, disability, catastrophizing, and avoidance behavior
Number of subjects: 97
Study 26736023 — intervention group
Group type: COMPARATOR
Intervention: Pain-free controls
Number of subjects: 97
Study 24950708 — intervention group
Group type: EXPERIMENTAL
Intervention: Eban II intervention
Number of subjects: 200
Study 22804945 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhubarb, montmorillonite powder combined with blood purification
Number of subjects: 39
Study 22804945 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 39
Study 20387081 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan 15 mg
Number of subjects: 18
Study 20387081 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan 30 mg
Number of subjects: 18
Study 20387081 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan 60 mg
Number of subjects: 18
Study 18825655 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions to improve blood pressure control delivered to both patients and providers
Number of subjects: 0
Study 18825655 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive quadrature
Number of subjects: 0
Study 18825655 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian methods
Number of subjects: 0
Study 18825655 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline and final measurement analysis
Number of subjects: 0
Study 15942771 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hyperoxia (FIO2 = 30%)
Number of subjects: 16
Study 15942771 — intervention group
Group type: COMPARATOR
Intervention: Normoxia
Number of subjects: 16
Study 12858483 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal Cytotec
Number of subjects: 276
Study 12858483 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin
Number of subjects: 276
Study 12858483 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytotec
Number of subjects: 276
Study 10473885 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU) therapy for 5 months
Number of subjects: 8
Study 8739934 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaine hydrochloride during cardioplegia
Number of subjects: 74
Study 8739934 — intervention group
Group type: EXPERIMENTAL
Intervention: Central anastomoses performed during cardiac arrest
Number of subjects: 74
Study 1929683 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg hydrochlorothiazide
Number of subjects: 51
Study 1929683 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg hydrochlorothiazide
Number of subjects: 51
Study 1929683 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (both doses)
Number of subjects: 51
Study 7201757 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin (1 mg/kg)
Number of subjects: 40
Study 7201757 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin (1 mg/kg)
Number of subjects: 40
Study 7201757 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin (500 mg)
Number of subjects: 40
Study 7201757 — intervention group
Group type: COMPARATOR
Intervention: Control (no antibiotic)
Number of subjects: 40
Study 30907562 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 154
Study 30907562 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib
Number of subjects: 154
Study 30907562 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of trastuzumab and lapatinib
Number of subjects: 154
Study 28045953 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CPM) 750 mg/m2 body surface area
Number of subjects: 138
Study 28045953 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone (MP) 1g
Number of subjects: 138
Study 28045953 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CPM)
Number of subjects: 138
Study 24910962 — intervention group
Group type: EXPERIMENTAL
Intervention: House Officers (HOs)
Number of subjects: 173
Study 24910962 — intervention group
Group type: COMPARATOR
Intervention: Faculty
Number of subjects: 173
Study 23999279 — intervention group
Group type: EXPERIMENTAL
Intervention: MD‐I (physician intervention)
Number of subjects: 574
Study 23999279 — intervention group
Group type: EXPERIMENTAL
Intervention: PT‐I (patient intervention)
Number of subjects: 574
Study 23999279 — intervention group
Group type: EXPERIMENTAL
Intervention: MD‐I and PT‐I
Number of subjects: 574
Study 21198798 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA cream applied twice daily before UV irradiation
Number of subjects: 21
Study 21198798 — intervention group
Group type: COMPARATOR
Intervention: Control cream applied twice daily before UV irradiation
Number of subjects: 21
Study 21198798 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA cream applied after UV irradiation
Number of subjects: 21
Study 21198798 — intervention group
Group type: COMPARATOR
Intervention: Control cream applied after UV irradiation
Number of subjects: 21
Study 18275343 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory exercise training (CET)
Number of subjects: 0
Study 18275343 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise control groups
Number of subjects: 0
Study 18275343 — intervention group
Group type: COMPARATOR
Intervention: Non-exercising groups
Number of subjects: 0
Study 17138300 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm infant massage
Number of subjects: 40
Study 17138300 — intervention group
Group type: COMPARATOR
Intervention: Observation of preterm infants receiving massage
Number of subjects: 40
Study 14689371 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (40 mg for the first two weeks, 80 mg for 5.5 months, and 40 mg for the last two weeks)
Number of subjects: 140
Study 14689371 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (47.5 mg for two weeks, 95 mg for 5.5 months, and 47.5 mg for the last two weeks)
Number of subjects: 140
Study 14689371 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan and Metoprolol (both groups)
Number of subjects: 140
Study 10631628 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg sumatriptan succinate alone
Number of subjects: 12
Study 10631628 — intervention group
Group type: COMPARATOR
Intervention: 100 mg sumatriptan succinate with 500 mg naproxen
Number of subjects: 12
Study 9048267 — intervention group
Group type: EXPERIMENTAL
Intervention: β-Blockers (carvedilol and bisoprolol)
Number of subjects: 0
Study 9048267 — intervention group
Group type: COMPARATOR
Intervention: Converting enzyme inhibitors
Number of subjects: 0
Study 9048267 — intervention group
Group type: EXPERIMENTAL
Intervention: β-Blockers
Number of subjects: 0
Study 9048267 — intervention group
Group type: EXPERIMENTAL
Intervention: Future studies (β-blocker Evaluation Survival Trial - BEST)
Number of subjects: 0
Study 1586070 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow-by CPAP
Number of subjects: 9
Study 1586070 — intervention group
Group type: EXPERIMENTAL
Intervention: Demand-flow CPAP
Number of subjects: 9
Study 1586070 — intervention group
Group type: EXPERIMENTAL
Intervention: Demand-flow CPAP with 5 cm H2O pressure support (DF-PS5)
Number of subjects: 9
Study 1586070 — intervention group
Group type: COMPARATOR
Intervention: Continuous-flow CPAP (CF CPAP)
Number of subjects: 9
Study 3897550 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive relaxation
Number of subjects: 7
Study 3897550 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-control relaxation
Number of subjects: 7
Study 3897550 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 7
Study 31061026 — intervention group
Group type: EXPERIMENTAL
Intervention: Swedish as native language (SNL)
Number of subjects: 641
Study 31061026 — intervention group
Group type: COMPARATOR
Intervention: Other native language (ONL)
Number of subjects: 641
Study 29775461 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training with at least modest weight loss (≥3%)
Number of subjects: 163
Study 29775461 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercise training without modest weight loss (<3%)
Number of subjects: 163
Study 29775461 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise groups
Number of subjects: 163
Study 27391900 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 months of intermittent anti-tuberculous therapy under DOTS (86 women)
Number of subjects: 175
Study 25863554 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcard campaign
Number of subjects: 6050
Study 25863554 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Information Technology (HIT) system
Number of subjects: 6050
Study 25863554 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined HIT and postcard intervention
Number of subjects: 6050
Study 23661768 — intervention group
Group type: EXPERIMENTAL
Intervention: QoL feedback with standard psychiatric assessment
Number of subjects: 124
Study 23661768 — intervention group
Group type: COMPARATOR
Intervention: Standard psychiatric assessment
Number of subjects: 124
Study 23661768 — intervention group
Group type: COMPARATOR
Intervention: QoL assessment with standard psychiatric assessment
Number of subjects: 124
Study 21415777 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel and cisplatin (DP) chemotherapy
Number of subjects: 200
Study 21415777 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin C, vindesine, and cisplatin (MVP) chemotherapy
Number of subjects: 200